Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
1.
An. Fac. Med. (Perú) ; 84(4)dic. 2023.
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1533576

RESUMO

Introducción. La aspergilosis invasiva presenta alta mortalidad en pacientes con enfermedades crónicas e inmunocomprometidos. Aspergillus fumigatus sensu stricto (AFSS) es el principal agente etiológico y su tipificación requiere de métodos moleculares. La incidencia incrementada de AI resistentes a los antifúngicos demanda un diagnóstico certero y oportuno. Métodos. Se estudiaron 20 cepas de la micoteca del Instituto de Medicina Tropical - Universidad Nacional Mayor de San Marcos, aisladas de muestras respiratorias e identificadas como Aspergillus fumigatus sensu lato mediante el estudio macroscópico y microscópico. Las cepas fueron referidas a la Universidad Nacional del Litoral para su tipificación mediante una PCR screening para AFSS basada en secuencias del gen CYP51A y el estudio de sensibilidad antifúngica para voriconazol (VOR), itraconazol (ITC), posaconazol (POS), isavuconazol (ISA), anidulafungina (ANF), caspofungina (CSF) y anfotericina B (AMB) obteniendo la concentración inhibitoria mínima (CIM) mediante el protocolo de CLSI M38M51S-Ed3. Resultados. Las 20 cepas fueron identificadas como AFSS. Ninguna de las cepas tuvo una CIM por encima del punto de corte clínico (VOR), ni epidemiológico (ITC, ISA, AMB y CSF). POS fue la droga más potente frente a la colección de cepas evaluadas (media geométrica (GM) de CIM de 0,042 µg/ml). Conclusiones. Todos los aislamientos fueron tipificados como AFSS sensibles a los azoles según los puntos de corte clínico, posaconazol tuvo la mayor actividad antifúngica. Nuestros hallazgos aportan a incrementar la escasa información sobre la etiología y sensibilidad a los antifúngicos de uso clínico de las aspergilosis invasiva en nuestro país.


Introduction. Invasive Aspergillosis (IA) poses a significant threat to patients with chronic diseases and compromised immune systems, with Aspergillus fumigatus sensu stricto (AFSS) being the primary etiological agent. Accurate and timely diagnosis is crucial, particularly given the rising incidence of IA strains resistant to antifungals, necessitating molecular methods for typing. Methods. Twenty strains from Instituto de Medicina Tropical - Universidad Nacional Mayor de San Marcos, mycological collection, previously identified as Aspergillus fumigatus sensu lato through macroscopic and microscopic analysis, were studied. These strains were forwarded to the Universidad Nacional del Litoral for AFSS typing using a PCR screening based on CYP51A gene sequences. Antifungal susceptibility testing was performed for Voriconazole (VOR), Itraconazole (ITC), Posaconazole (POS), Isavuconazole (ISA), Anidulafungin (ANF), Caspofungin (CSF), and Amphotericin B (AMB), obtaining Minimum Inhibitory Concentrations (MICs) according to CLSI M38M51S-Ed3. Results. All 20 strains were identified as AFSS. None of the strains exhibited MICs above the clinical breakpoint (VOR) or the epidemiological cutoffs (ITC, ISA, AMB, and CSF). POS demonstrated the highest potency against the strain collection, with a geometric mean MIC of 0,042 µg/ml. Conclusions. All isolates were classified as azole-sensitive Aspergillus fumigatus sensu stricto (AFSS) based on clinical cutoff points, particularly posaconazole, which exhibited superior antifungal activity. Our findings contribute to augmenting the limited information on the etiology and clinical antifungal sensitivity of IA in our country.

2.
Rev Iberoam Micol ; 39(2): 54-56, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35788316

RESUMO

BACKGROUND: Trichosporon asahii, an emerging fungal pathogen, has been frequently associated with invasive infections in critically ill patients. CASE REPORT: A 74-year-old male patient diagnosed with COVID-19 was admitted to an Intensive Care Unit (ICU). During hospitalization, the patient displayed episodes of bacteremia by Staphylococcus haemolyticus and a possible urinary tract infection by T. asahii. While the bacterial infection was successfully treated using broad-spectrum antibiotics, the fungal infection in the urinary tract was unsuccessfully treated with anidulafungin and persisted until the patient died. CONCLUSIONS: With the evolving COVID-19 pandemic, invasive fungal infections have been increasingly reported, mainly after taking immunosuppressant drugs associated with long-term broad-spectrum antibiotic therapy. Although Candida and Aspergillus are still the most prevalent invasive fungi, T. asahii and other agents have emerged in critically ill patients. Therefore, a proper surveillance and diagnosing any fungal infection are paramount, particularly in COVID-19 immunocompromised populations.


Assuntos
COVID-19 , Micoses , Trichosporon , Tricosporonose , Infecções Urinárias , Idoso , Antifúngicos/uso terapêutico , Basidiomycota , Estado Terminal , Humanos , Masculino , Micoses/tratamento farmacológico , Micoses/microbiologia , Pandemias , Tricosporonose/diagnóstico , Tricosporonose/tratamento farmacológico , Tricosporonose/microbiologia , Infecções Urinárias/tratamento farmacológico , Infecções Urinárias/microbiologia
3.
Rev. iberoam. micol ; 39(2): 54-56, abril 2022. ilus
Artigo em Inglês | IBECS | ID: ibc-207103

RESUMO

Background:Trichosporon asahii, an emerging fungal pathogen, has been frequently associated with invasive infections in critically ill patients.Case report:A 74-year-old male patient diagnosed with COVID-19 was admitted to an Intensive Care Unit (ICU). During hospitalization, the patient displayed episodes of bacteremia by Staphylococcus haemolyticus and a possible urinary tract infection by T. asahii. While the bacterial infection was successfully treated using broad-spectrum antibiotics, the fungal infection in the urinary tract was unsuccessfully treated with anidulafungin and persisted until the patient died.Conclusions:With the evolving COVID-19 pandemic, invasive fungal infections have been increasingly reported, mainly after taking immunosuppressant drugs associated with long-term broad-spectrum antibiotic therapy. Although Candida and Aspergillus are still the most prevalent invasive fungi, T. asahii and other agents have emerged in critically ill patients. Therefore, a proper surveillance and diagnosing any fungal infection are paramount, particularly in COVID-19 immunocompromised populations. (AU)


Antecedentes:Trichosporon asahii, un hongo patógeno emergente, se ha asociado con frecuencia con infecciones invasivas en pacientes enfermos en estado crítico.Caso clínico:Un paciente de sexo masculino de 74 años de edad, con diagnóstico positivo para la COVID-19, ingresó en una unidad de cuidados intensivos. Durante la hospitalización el paciente presentó episodios de bacteriemia por Staphylococcus haemolyticus y una posible infección del tracto urinario por T. asahii. Mientras la infección bacteriana fue tratada exitosamente con antibióticos de amplio espectro, la infección micótica urinaria no remitió con anidulafungina y persistió hasta la muerte del paciente.Conclusiones:Con la pandemia de la COVID-19 se han notificado cada vez más casos de infecciones micóticas invasivas, principalmente después del uso de fármacos inmunosupresores, asociados con terapia de antibióticos de amplio espectro. Aunque Candida y Aspergillus siguen siendo los hongos invasores más prevalentes, T.asahii y otras especies han emergido en pacientes enfermos en estado crítico. Por lo tanto, la vigilancia y el diagnóstico de las infecciones micóticas es primordial, particularmente en poblaciones inmunodeficientes por la COVID-19. (AU)


Assuntos
Humanos , Antifúngicos/uso terapêutico , Basidiomycota , Estado Terminal , Micoses/tratamento farmacológico , Trichosporon , Infecções por Coronavirus/epidemiologia , Pandemias , Tricosporonose/diagnóstico , Tricosporonose/tratamento farmacológico , Tricosporonose/microbiologia , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave , Infecções Urinárias/tratamento farmacológico , Infecções Urinárias/microbiologia
4.
O.F.I.L ; 32(2): 207-208, enero 2022. ilus
Artigo em Espanhol | IBECS | ID: ibc-205758

RESUMO

La córnea es la membrana transparente en forma de disco abombado, que constituye la parte anterior del globo ocular y se halla delante del iris. La infecciones de este tejido son muy comunes y pueden llegar a producir ulceras. Un tratamiento retardado o inadecuado puede dar lugar a complicaciones, una de estas puede ser la perforación corneal. (AU)


The cornea is the transparent membrane in the form of a bulging disc, which forms the front part of the eyeball and is located in front of the iris. Infections of this tissue are very common and can lead to ulcers. Delayed or inadequate treatment can lead to complications, one of which can be corneal perforation. (AU)


Assuntos
Humanos , Feminino , Adulto , Córnea , Perfuração da Córnea , Diagnóstico , Conjuntivite , Pacientes , Terapêutica
5.
Infectio ; 24(4): 217-223, oct.-dic. 2020. tab, graf
Artigo em Espanhol | LILACS, COLNAL | ID: biblio-1114872

RESUMO

Resumen Candida spp. es un agente etiológico importante en infecciones del tracto urinario, principalmente en población con terapia antimicótica de amplio espectro y con catéteres urinarios. Candida albicans es la especie más frecuente, pero otras especies han surgido como patógenos emergentes. En este trabajo se recolectaron aislamientos de Candida spp. de urocultivos de pacientes que consultaron en Dinamica IPS entre enero 2016 y noviembre 2017. Para estimar la frecuencia de las especies y observar los patrones de sensibilidad, se realizó la identificación fenotípica y su perfil de sensibilidad con el sistema comercial Vitek 2® (BioMérieux, Inc.), adicionalmente se evaluaron mediante análisis de las secuencia y filogenética ITS1-5.8S-ITS2. En el estudio se incluyeron 78 aislamientos de Candida spp. Las frecuencias de especies de Candida identificadas empleando las herramientas moleculares fueron: C. albicans (38,5%), C. tropicalis (23,1%), C. glabrata (21,8%), C. parapsilosis (10,3%), C. metapsilosis y C. krusei (2,5%) y C. guillermondi (1,3%). La identificación por métodos moleculares y por el sistema Vitek 2 fue: C. albicans (93,3%), C. glabrata (94,1%), C. tropicalis (83,3%), C. parapsilosis (75%) C. guilliermondii y C. krusei (100%). La sensibilidad de todos los aislamientos al fluconazol fue 93,6%.


Abstract Candida spp is an important etiologic agent in urinary tract infections, mainly in patients in broad-spectrum antifungal therapy, with urinary catheters. Candida albicans is the most frequent specie; but other species have arised as emerging pathogens. In this study, isolates of Candida spp. of urine cultures from patients who consulted in Dinamica IPS between January 2016 and November 2017 were evaluated. To estimate the frequency of the species and to observe the sensitivity patterns, the phenotypic identification and its sensitivity profile was performed employed the Vitek 2® commercial system. (BioMérieux, Inc) In addition the isolates were evaluated by sequence analysis and phylogenetics ITS1-5.8S-ITS2. This study included 78 isolates of Candida spp. The frequencies of Candida species identified using the molecular tools were: C. albicans (38.5%), C. tropicalis (23.1%), C. glabrata (21.8%), C. parapsilosis (10.3%), C. guillermondi (1.3%) and C. metapsilosis and C. krusei (2.5%). The identification by molecular methods and by Vitek 2 system were: C. albicans (93.3%), for C. glabrata (94.1%), C. tropicalis (83.3%), C. parapsilosis (75%) and 100% for C. guilliermondii and C. krusei.. fluconazole sensitivity of all isolates was 93.6%


Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Candida , Técnicas de Diagnóstico Urológico , Candida parapsilosis , Laboratórios , Sistema Urinário , Infecções Urinárias , Candida albicans , Fluconazol , Análise de Sequência , Cateteres Urinários , Infecções
6.
Rev. chil. infectol ; 37(2): 124-128, abr. 2020. tab
Artigo em Espanhol | LILACS | ID: biblio-1126098

RESUMO

Resumen Introducción: Las infecciones por levaduras del género Cryptococcus afectan principalmente a pacientes con déficit de la inmunidad mediada por células. Han sido escasos los estudios de sensibilidad realizados para este género en Chile. Objetivos: Determinar la sensibilidad in vitro de Cryptococcus sp a antifúngicos de uso habitual y evaluar la concordancia esencial entre sensibilidad determinada por microdilución en caldo y por difusión en agar con tiras comerciales. Materiales y Método: Estudio descriptivo de 21 cepas aisladas desde liquido céfalo-raquídeo y sangre. Las CIM50 y CIM90 para fluconazol, voriconazol y anfotericina B se determinaron por microdilución en caldo (Sensititre Yeast One®) y por difusión en agar con tiras comerciales (MIC Test Strips). Resultados: Todas las cepas correspondieron a C. neoformans. Los rangos de CIM50 y CIM90 para cada antifúngico estudiado fueron amplios por ambos métodos. La concordancia esencial entre microdilución y difusión en agar con tiras comerciales fue de 24, 62 y 29% para fluconazol, voriconazol y anfotericina B, respectivamente. Conclusiones: La prueba de Sensititre Yeast One® y la de difusión en agar con tiras comerciales, MIC Test Strips, tienen una pobre concordancia esencial para fluconazol y anfotericina B.


Abstract Background: Cryptococcus yeast infections primarily affect immunocompromised patients. There have been few susceptibility studies conducted for this genus in Chile. Aims: To determine the in vitro susceptibility to commonly used antifungals and evaluate the concordance between susceptibility determined by microdilution in broth and commercially available strips. Methods: Descriptive study of 21 Cryptococcus strains, isolated from cerebrospinal fluid and blood. The MIC50 and MIC90 for fluconazole, voriconazole and amphotericin B was determined by broth microdilution (Sensititre Yeast One®) and by commercial drug sensitivity strips (MIC Test Strips). Results: All strains corresponded to C. neoformans. The ranges of MIC50 and MIC90 for each antifungal studied were wide by both methods. The essential agreement between Sensititre Yeast One test and strips was 24, 62 and 29% for fluconazole, voriconazole and amphotericin B, respectively. Conclusions: The Sensititre Yeast One test and MIC Test Strips exhibited poor essential concordance, especially for fluconazole and amphotericin B.


Assuntos
Humanos , Criptococose , Cryptococcus neoformans , Testes de Sensibilidade Microbiana , Fluconazol , Chile , Antifúngicos
7.
Colomb. med ; 50(4): 293-298, Oct.-Dec. 2019.
Artigo em Inglês | LILACS | ID: biblio-1114722

RESUMO

Abstract Background: Candida auris is an emerging yeast frequently reported as resistant to multiple antifungal drugs commonly used to treat Candida infections. This specie can colonize the patient's skin and has great ability for producing outbreaks in hospitals. C. auris is phylogenetically related to other Candida species, can be misidentified using conventional biochemical or commercial methods and requires specific technology for its identification. Case report: We report the first isolate of C. auris in Cali, Colombia, from a central venous catheter in a 37-year-old patient with rheumatoid arthritis and endocarditis who did not have symptoms of sepsis. The yeast was initially misidentified as C. haemulonii using the Phoenix system and subsequently identified as C. auris by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS). The broth microdilution method was used to determine the minimum inhibitory concentration; the isolate was susceptible to fluconazole, itraconazole, voriconazole and amphotericin B. Conclusions: This report contributes to knowledge of the epidemiology of C. auris infections in individuals with underlying disease and describes an isolate with a behavior different from what is usually reported.


Resumen Antecedentes: Candida auris es una levadura emergente, informada con frecuencia como resistente a diversos antifúngicos usados comúnmente para tratar infecciones por Candida. Esta especie puede colonizar la piel y tiene gran capacidad de producir brotes en ambientes hospitalarios. Está filogenéticamente relacionada con otras especies de Candida, es mal identificada por los métodos bioquímicos o comerciales, y requiere tecnología específica para su identificación. Reporte de caso: Se informa el primer aislamiento de C. auris en Cali, Colombia en un paciente de 37 años con artritis reumatoide y endocarditis, sin síntomas de sepsis, a partir de la punta de catéter venoso central. La levadura inicialmente se identificó como C. haemulonii por el sistema Phoenix® y posteriormente como C. auris por espectrometría de masas desorción/ionización láser asistida por una matriz con detección de masas por tiempo de vuelo (MALDI-TOF MS). Se determinó la concentración inhibitoria mínima por el método de microdilución en caldo que mostró un aislamiento sensible a fluconazol, itraconazol, voriconazol y anfotericina B. Conclusión: Este informe contribuye al conocimiento de la epidemiología de las infecciones por C. auris en individuos con enfermedad subyacente y describe un aislamiento con un comportamiento diferente a lo indicado en otros estudios.


Assuntos
Adulto , Humanos , Masculino , Candida/isolamento & purificação , Candidíase/diagnóstico , Infecções Relacionadas a Cateter/diagnóstico , Antifúngicos/administração & dosagem , Candidíase/microbiologia , Candidíase/tratamento farmacológico , Cateterismo Venoso Central/efeitos adversos , Testes de Sensibilidade Microbiana , Colômbia , Infecções Relacionadas a Cateter/microbiologia , Infecções Relacionadas a Cateter/tratamento farmacológico
8.
Rev Iberoam Micol ; 36(3): 115-119, 2019.
Artigo em Espanhol | MEDLINE | ID: mdl-31300300

RESUMO

BACKGROUND: Candida albicans is a microorganism frequently involved in several infections; the patient's oral cavity, caries niches or periodontal disease can sometimes be the reservoir.. The fungal resistance to the available treatments, among other reasons, has led to the search for new antifungal alternatives. AIMS: To carry out a comparative study of the in vitro effects of diethylstilboestrol (DES) and fluconazole (FLZ) on the growth of clinical strains of C. albicans. METHODS: Seven strains of C. albicans were used: a) one FLZ-sensitive culture collection strain, ATCC 90028 (ATCC); b) four oral isolates from four oncological patients with periodontal disease (period 8, 9, 10, and 11); and c) two oral isolates from an AIDS patient with oropharyngeal candidiasis: one FLZ- sensitive (2-76), and another FLZ- resistant (12-99). The MIC was evaluated by standard spectrophotometric techniques using the CLSI (M27-A3) guidelines. The inhibitory concentration 50% (IC50) was calculated using functional analysis with the Graph Pad software. RESULTS: DES inhibited the growth of all C. albicans strains, whether sensitive or resistant to FLZ. Experimental data fitted non-linear functions of inhibitor concentration versus response. Minimum inhibitory concentrations (MIC) for DES and FLZ were as follows: 28.18µg/ml and 4.90µg/ml (ATCC); 17.16µg/ml and 3.14µg/ml (period); 27.64µg/ml and 4.22µg/ml (2-76); 6.16µg/ml and 438.19µg/ml (12-99), respectively. CONCLUSIONS: DES showed antifungal activity on all clinical C. albicans strains isolated from patients with dental and medical diseases. It showed the highest potency on the FLZ-resistant isolate.


Assuntos
Antifúngicos/farmacologia , Candida albicans/efeitos dos fármacos , Dietilestilbestrol/farmacologia , Farmacorresistência Fúngica , Fluconazol/farmacologia , Humanos , Testes de Sensibilidade Microbiana
9.
Artigo em Espanhol | LILACS-Express | LILACS | ID: biblio-1536999

RESUMO

El propóleos es una resina colectada por las abejas Apis mellifera de especies botánicas, próximas a los apiarios. Este material resinoso es ampliamente reconocido por sus propiedades antimicrobianas. El objetivo de este trabajo fue evaluar la actividad antifúngica in vitro de los extractos etanólicos de propóleos (EEP), obtenidos a partir de muestras provenientes de apiarios experimentales de investigación, ubicados en la región del Bajo Cauca antioqueño, sobre dos hongos filamentosos, Botryodiplodia theobromae y Fusarium oxysporum y un hongo levaduriforme, Candida albicans El propóleos fue recolectado por los métodos de malla y de raspado, durante diferentes periodos del año. Mediante la técnica de macrodilución en caldo, se evaluaron seis dosis de EEP, en un rango de156 a 5000µgmL-1 y se determinó la concentración que inhibió el 80 y el 50% del crecimiento del hongo. Los resultados indican que el método de recolección del propóleos presentó diferencias significativas con respecto al crecimiento de C albicans y no para B theobromae y F oxysporum Las CMI80 estuvieron entre 1211 a 4050µgmL-1, 1567 a 5016µgmL-1 y 1529 a 3568µgmL-1 para B theobromae, F oxysporum y C albicans, respectivamente. En conclusión, los extractos evaluados exhibieron un actividad inhibitoria del crecimiento moderada, en comparación con el control y el hongo levaduriforme, C albicans presentó la mayor sensibilidad frente a los EEP analizados. Adicionalmente, el método de recolección del propóleos solo presentó diferencias significativas respecto a la concentración mínima inhibitoria, encontrada para C albicans.


Propolis is a resin collected by the Apis mellifera bees from botanical species surrounding the apiaries. This resinous material is widely renowned by its antimicrobial properties. The aim of this research was to evaluate the in vitro activity of ethanolic extracts from propolis (EEP), obtained from experimental research apiaries located in the Bajo Cauca antioqueño region, against two filamentous fungi, Botryodiplodia theobromae and Fusarium oxysporum, and a yeast, Candida albicans. Propolis were collected in different periods of the year, by methods of scraping and mesh. Using the macrodilution technique, six doses of EEP ranging from 156 to 5000µgmL-1 were evaluated and minimal inhibitory concentration 80 and inhibitory concentration 50 were determined. Results indicated that the harvest method showed a significant effect on C albicans growth, but not for B theobromae and F oxysporum. The MICs80 observed were between 1211 to 4050µgmL-1, 1567 to 5016µgmL-1 and 1529 to 3568µgmL-1 for B theobromae, F oxysporum and C albicans, respectively. In conclusion, the extracts tested showed a moderate inhibitory growth activity, in comparison with the control; the yeast, C albicans, showed the highestsensibility to the EEP evaluated. Additionally, the collection methods only showed significant differences with respect to minimal inhibitory concentration found for C albicans.

10.
Medisan ; 18(9)sep. 2014.
Artigo em Espanhol | CUMED | ID: cum-58329

RESUMO

Las infecciones micóticas invasivas han alcanzado tal importante diseminación en las unidades de cuidados intensivos, que hoy constituyen la cuarta causa de infecciones adquiridas en este servicio, con una mortalidad de hasta 50 por ciento. La inmunodepresión propia del paciente en estado crítico, unido a la aplicación de determinados procedimientos traumáticos -- catéteres, sondas, endoscopias, ventilación, intervenciones quirúrgicas abdominales, nutrición parenteral, entre otros --, predisponen a la infección. Al respecto, se está empleando una gama de nuevos antimicóticos (triazoles y equiniocandinas) en el tratamiento de pacientes con micosis invasivas, sobre la base de que la creación de protocolos terapéuticos puede disminuir el índice de mortalidad por dichas afecciones(AU)


The invasive fungal infections have reached such an important dissemination in the intensive care units that today they constitute the fourth cause of acquired infections in this service, with a mortality of up to 50 percent. The immunodepression characteristic of the patient in critical state, together to the application of certain traumatic procedures -- catheters, probes, endoscopies, ventilation, abdominal surgical interventions, parenteral nutrition, among other --, predispose to the infection. In this respect, a range of new antifungal drugs are being used (triazoles and equiniocandines) in the treatment of patients with invasive mycosis, on the base that the creation of therapeutic protocols can decrease the mortality index caused by these disorders(AU)


Assuntos
Humanos , Masculino , Feminino , Candidíase/terapia , Antifúngicos/uso terapêutico , Triazóis , Equinocandinas
11.
Rev Iberoam Micol ; 31(2): 145-8, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-23680638

RESUMO

BACKGROUND: Few studies exist on prevalence of fungemia by Candida orthopsilosis, with variable results. AIMS: To study the incidence, epidemiology and antifungal susceptibility of C. orthopsilosis strains isolated from fungemias over two years at a tertiary hospital. METHODS: Candidemia episodes between June 2007 and June 2009 in a university hospital (Puerta del Mar, Cádiz, Spain) were studied. The strains initially identified as Candida parapsilosis were genotypically screened for C. parapsilosis sensu stricto, C. orthopsilosis and Candida metapsilosis, and their antifungal susceptibility was evaluated. RESULTS: In this period 52 cases of candidemia were documented. Of the 19 strains originally identified as C. parapsilosis, 13 were confirmed as C. parapsilosis sensu stricto and 6 as C. orthopsilosis. Of the 52 isolates, the most frequent species were Candida albicans (30.8%), C. parapsilosis sensu stricto (25%), C. orthopsilosis, Candida tropicalis and Candida glabrata in equal numbers (11.5%). C. orthopsilosis isolates were susceptible to amphotericin B, caspofungin, voriconazole and fluconazole, with no significant differences in MIC values with C. parapsilosis sensu stricto. The source of isolates of C. orthopsilosis were neonates (50%) and surgery (50%), and 100% were receiving parenteral nutrition; however C. parapsilosis sensu stricto was recovered primarily from patients over 50 years (69.2%) and 46.1% were receiving parenteral nutrition. CONCLUSIONS: These findings show that C. orthopsilosis should be considered as human pathogenic yeast and therefore its accurate identification is important. Despite our small sample size our study suggests that a displacement of some epidemiological characteristics previously attributed to C. parapsilosis to C. orthopsilosis may be possible.


Assuntos
Antifúngicos/uso terapêutico , Candida/isolamento & purificação , Candidemia/microbiologia , Infecção Hospitalar/microbiologia , Centros de Atenção Terciária/estatística & dados numéricos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antifúngicos/farmacologia , Candida/classificação , Candida/efeitos dos fármacos , Candidemia/tratamento farmacológico , Candidemia/epidemiologia , Criança , Pré-Escolar , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/epidemiologia , Farmacorresistência Fúngica , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Técnicas de Tipagem Micológica , Prevalência , Estudos Retrospectivos , Espanha/epidemiologia , Especificidade da Espécie , Adulto Jovem
12.
West Indian med. j ; 62(8): 724-730, Nov. 2013. tab
Artigo em Inglês | LILACS | ID: biblio-1045741

RESUMO

OBJECTIVE: Candidaemia is the fourth most common cause of nosocomial bloodstream infections. The objective of this paper was to evaluate the risk factors associated with mortality in patients with candidaemia with respect to Candida species and their susceptibilities, retrospectively. METHODS: All consecutive patients who developed candidaemia at an 800-bed training and research hospital were enrolled in this retrospective, observational, single centre study during the period June 2006 to December 2011. RESULTS: A total of 97 candidaemia episodes were identified in 97 patients during the study period with an overall incidence of four episodes/10 000 admissions in adults. Crude 30-day mortality rates among patients with candidaemia were 56% (55 of 97 cases). Urinary catheterization, immunosuppressive therapy, acute physiology and chronic health evaluation (APACHE) II score (>16) and hypoal-buminaemia were found to be independent risk factors for fatal candidaemia. CONCLUSIONS: Adult cases with candidaemia who have risk factors associated with mortality are more likely to have poor prognosis despite appropriate and timely initiated antifungal drug treatment. Empiric antifungal drug should be tailored according to the severity of the patients ' conditions and local antifungal susceptibility.


OBJETIVO: La candidemia es la cuarta causa más común de infecciones nosocomiales del flujo sanguíneo. El objetivo del presente trabajo fue evaluar los factores de riesgo asociados con la mortalidad en pacientes con candidemia con respecto a las especies de Candida y sus susceptibilidades, de manera retrospectiva. MÉTODOS: Todos los pacientes consecutivos que desarrollaron candidemia en un hospital de capacitación e investigación de 800 camas, fueron inscritos en este estudio retrospectivo, observacional, monocéntrico, durante el período de junio de 2006 a diciembre de 2011. RESULTADOS: Se identificaron un total de 97 episodios de candidemia en 97 pacientes durante el período de estudio con una incidencia general de cuatro episodios/10 000 ingresos en adultos. Las tasas brutas de mortalidad de 30 días entre los pacientes con candidemia fueron 56% (55 de 97 casos). Se halló que la cateterización urinaria, la terapia inmunosupresiva, y la puntuación (> 16) de la escala de Evaluación de la fisiología aguda y salud crónica (APACHE II) así como la hipoalbuminemia, constituyen factores de riesgo para una candidemia fatal. CONCLUSIONES: Los casos adultos con candidemia que tienen factores de riesgo asociados con mortalidad son más propensos a tener un pronóstico pobre a pesar del tratamiento apropiado y oportuno con medicamentos antimicóticos. Los antimicóticos empírico se deben adaptar según la severidad de las condiciones de los pacientes y la susceptibilidad antifúngica local.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Adulto Jovem , Candida/classificação , Farmacorresistência Fúngica Múltipla , Candidemia/microbiologia , Candidemia/mortalidade , Candida/efeitos dos fármacos , Incidência , Estudos Retrospectivos , Fatores de Risco
13.
Rev Iberoam Micol ; 30(4): 248-55, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23583265

RESUMO

BACKGROUND: Saprochaete capitata (formerly known as Geotrichum capitatum and Blastoschizomyces capitatus) is a ubiquitous fungus found in soil, water, air, plants and dairy products. It colonizes the skin, and bronchial and intestinal tract of healthy people producing serious opportunistic infections in patients with haematological malignancies, especially in those with acute leukaemia. Since 1960s its presence is being increasingly recognized in this group of patients. The clinical spectrum of S. capitata disseminated infections is very similar to that produced by Candida, being easily misinterpreted. The associated high mortality and low susceptibility to fluconazole and echinocandins of S. capitata require the acknowledgement of this emergent infection so that it can be properly treated. CASE REPORT: We report 5 new cases of S. capitata disseminated infection in patients with advanced haematological malignancies observed in the haematology unit between the years 2004 and 2010, and review the state-of-the-art for diagnosis and treatment of this infection. CONCLUSIONS: Based on our experience, the prophylactic use of or the empirical antifungal treatment with fluconazole and/or echinocandins would not be adequate for oncohaematological patients in those hospitals where S. capitata infection may be highly prevalent.


Assuntos
Antifúngicos/uso terapêutico , Infecção Hospitalar/microbiologia , Dipodascus/isolamento & purificação , Fungemia/microbiologia , Leucemia/complicações , Infecções Oportunistas/microbiologia , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Linfoma de Burkitt/complicações , Linfoma de Burkitt/tratamento farmacológico , Infecções Relacionadas a Cateter/tratamento farmacológico , Infecções Relacionadas a Cateter/microbiologia , Infecção Hospitalar/tratamento farmacológico , Dipodascus/efeitos dos fármacos , Farmacorresistência Fúngica , Quimioterapia Combinada , Evolução Fatal , Neutropenia Febril/induzido quimicamente , Feminino , Fungemia/tratamento farmacológico , Humanos , Hospedeiro Imunocomprometido , Leucemia/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Infecções Oportunistas/tratamento farmacológico
14.
Rev. bras. oftalmol ; 72(2): 132-141, mar.-abr. 2013. ilus, tab
Artigo em Português | LILACS | ID: lil-678383

RESUMO

O tratamento das infecções oculares por fungos representa um desafio à prática oftalmológica. Para obtermos resposta terapêutica adequada, além do uso da droga correta, é necessária a administração desta de forma eficaz. Este manuscrito reúne informações a respeito das principais drogas antifúngicas utilizadas em infecções oculares, suas concentrações e principais vias de administração.


Treatment of fungal eye infections represents a challenge to the ophthalmology practice. For an adequate therapeutic response, besides correct drug choice, it is necessary an effectively administration. This script gathers information about the major antifungal drugs used in eye infections, their concentrations and main administration routes.


Assuntos
Humanos , Antifúngicos/administração & dosagem , Antifúngicos/uso terapêutico , Interações Medicamentosas , Infecções Oculares Fúngicas/tratamento farmacológico , Azóis/administração & dosagem , Azóis/uso terapêutico , Equinocandinas/administração & dosagem , Equinocandinas/uso terapêutico , Pirimidinas/administração & dosagem , Pirimidinas/uso terapêutico , Polienos/administração & dosagem , Polienos/uso terapêutico
15.
Rev Iberoam Micol ; 30(3): 200-4, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23402831

RESUMO

BACKGROUND: Infections caused by Fusarium are difficult to treat because these fungi show in vitro and in vivo resistance to practically all the antifungal agents available, which explains the high mortality rates. An attempt to overcome fungal resistance is the combination of antifungal agents, especially those with different mechanisms of action. AIMS: Evaluate the in vitro interactions of combinations of voriconazole or itraconazole with other antifungal agents against 32 isolates of Fusarium spp.: Fusarium chlamydosporum, Fusarium oxysporum, Fusarium proliferatum and Fusarium solani. METHODS: Drug interactions were assessed by a checkerboard microdilution method that also included the determination of the MIC of each drug alone according to CLSI (Clinical and Laboratory Standards Institute) document M38-A2, 2008. RESULTS: The best combinations were voriconazole+terbinafine which showed synergism against 84% of Fusarium strains. Other synergistic combinations were voriconazole+itraconazole (50%), voriconazole+fluconazole (50%), voriconazole+miconazole (38%), voriconazole+flucytosine (22%) and voriconazole+ketoconazole (25%). The synergisms observed with itraconazole combinations were itraconazole+terbinafine (25%) and itraconazole+flucytosine (9.37%). The antagonisms observed were: voriconazole+fluconazole (3%) and itraconazole+flucytosine (12.5%). CONCLUSIONS: The synergism showed by voriconazole+terbinafine was remarkable. To better elucidate the potential usefulness of our findings, new in vivo and in vitro studies deserve be performed.


Assuntos
Antifúngicos/farmacologia , Fusarium/efeitos dos fármacos , Itraconazol/farmacologia , Voriconazol/farmacologia , Farmacorresistência Fúngica , Sinergismo Farmacológico , Flucitosina/farmacologia , Fusarium/classificação , Testes de Sensibilidade Microbiana , Naftalenos/farmacologia , Especificidade da Espécie , Terbinafina
16.
An. bras. dermatol ; 87(4): 561-565, July-Aug. 2012. tab
Artigo em Inglês | LILACS | ID: lil-645324

RESUMO

BACKGROUND: The standard methodology for determining the antifungal sensitivity against the Sporothrix schenckii complex recommends the use of the 1640 Roswell Park Memorial Institute culture medium (RPMI) buffered with morpholinepropanolsulfonic acid (MOPS). However, while this is a high-cost medium which requires a laborious implementation and sterilization by filtration, the Sabouraud dextrose broth is a low-cost medium, widely used in mycology, sterilized by autoclave. OBJECTIVE: To evaluate the performance of the Sabouraud dextrose broth culture medium as a substitute for the RPMI 1640-MOPS in determining the antifungal sensitivity of S. schenckii. METHODS: Forty-eight clinical isolates were evaluated against five antifungal agents: itraconazole, ketoconazole, fluconazole, amphotericin B and terbinafine, using the method of broth microdilution advocated by the M38-A2 protocol of the Clinical and Laboratory Standards Institute. RESULTS: There were no significant differences between the Minimum Inhibitory Concentrations obtained in the two culture media for all the antifungals, with the exception of the amphotericin B. Regarding this drug, the Minimum Inhibitory Concentration range obtained were wider for the Sabouraud dextrose broth than for the Roswell Park Memorial Institute morpholinepropanelsulfonic acid. CONCLUSIONS: The Sabouraud dextrose broth showed potential to be used in the in vitro evaluation of the S. schenckii complex antifungal activity.


FUNDAMENTOS: A metodologia padronizada para a determinação da sensibilidade aos antifúngicos frente ao complexo Sporothrix schenckii preconiza a utilização do meio de cultura Roswell Park Memorial Institute (RPMI) 1640 tamponado com ácido morfolinopropanosulfônico (MOPS). No entanto, este meio possui custo elevado, execução trabalhosa e esterilização por filtração. Já o caldo Sabouraud-dextrose é amplamente utilizado em micologia, de baixo custo e pode ser esterilizado por autoclavagem. OBJETIVO: Avaliar o desempenho do meio de cultura caldo Sabouraud-dextrose em substituição ao RPMI 1640-MOPS na determinação da sensibilidade de S. schenckii a antifúngicos. MÉTODO: Foram avaliados 48 isolados clínicos frente a cinco antifúngicos: itraconazol, cetoconazol, fluconazol, anfotericina B e terbinafina, utilizando a metodologia da microdiluição em caldo preconizada pelo protocolo M38-A2 do Clinical and Laboratory Standards Institute. RESULTADOS: Não houve diferenças significativas nas Concentrações Inibitórias Mínimas obtidas nos dois meios de cultura para todos os antifúngicos, com exceção da anfotericina B. Para este fármaco, foram obtidas faixas mais amplas de Concentrações Inibitórias Mínimas para caldo Sabouraud-dextrose do que para Roswell Park Memorial Institute-morfolinopropanosulfônico. CONCLUSÕES: O caldo Sabouraud-dextrose mostrou potencial para ser utilizado na avaliação in vitro da atividade antifúngica do complexo S. schenckii.


Assuntos
Humanos , Antifúngicos/farmacologia , Meios de Cultura/química , Sporothrix/efeitos dos fármacos , Anfotericina B/farmacologia , Meios de Cultura/economia , Fluconazol/farmacologia , Glucose/economia , Glucose/farmacologia , Itraconazol/farmacologia , Cetoconazol/farmacologia , Testes de Sensibilidade Microbiana/economia , Testes de Sensibilidade Microbiana/métodos , Naftalenos/farmacologia
17.
CES med ; 26(1): 71-83, ene.-jun. 2012. tab
Artigo em Espanhol | LILACS | ID: lil-652808

RESUMO

El aumento creciente de infecciones fúngicas y la aparición de resistencia a los antimicóticos,han hecho necesario el desarrollo de métodos estandarizados para la determinación dela susceptibilidad antifúngica. Tales métodos deben ser reproducibles y adaptables a un laboratorioasistencial, de manera que permitan la detección de resistencia in vitro, la cual, en la mayoría delos casos, suele correlacionarse con una evolución clínica desfavorable. Tanto el Clinical LaboratoryStandards Institute, como el European Committee for Antimicrobial Susceptibility Testing han desarrolladoguías para la medición estandarizada de la sensibilidad de varias especies de hongos a losantimicóticos actuales. En la literatura científica colombiana son pocos los datos disponibles sobrela sensibilidad antifúngica, por lo que frente al creciente aumento de la resistencia a los antifúngicos,se hace necesario comenzar a recopilar datos propios. En este artículo se hace una revisión de lasúltimas publicaciones indexadas en Pubmed con relación a los distintos métodos disponibles paramedir la sensibilidad antifúngica y, adicionalmente, se destaca su utilidad en la práctica clínica.


The increasing number of fungal infections andthe emergence of antifungal resistance, have prompted the development of standardized methods for determining antifungal sensitivityprofiles, aiming at obtaining reproducible andadaptable tests that could be done in hospital laboratories for the in vitro determination of resistanceas, in most cases, data correlate withan unsatisfactory clinical outcome. Both the Clinical Laboratory Standards Institute (CLSI)and the European Committee for AntimicrobialSusceptibility Testing (EUCAST), have developed guidelines for the interpretation of standardized sensitivity measurements of the various fungalspecies to current antifungal compounds.In the Colombian scientific literature, few data are available on antifungal sensitivity; however,with the increasing number of antifungal resistant isolates, it is necessary to begin collecting our own data. This paper reviews recent publicationsin PubMed regarding the various methods of antifungal susceptibility testing and highlights their usefulness in clinical practice.


Assuntos
Humanos , Antifúngicos , Fungos , Testes de Sensibilidade Microbiana , Leveduras
18.
Rev. Assoc. Med. Bras. (1992) ; 58(3): 308-318, May-June 2012. ilus, tab
Artigo em Português | LILACS | ID: lil-639554

RESUMO

OBJETIVO: Avaliar e comparar a eficácia dos antifúngicos tópicos empregados no tratamento de cada dermatomicose. MÉTODOS: Foi desenvolvida uma revisão sistemática de ensaios clínicos randomizados, publicados em português, espanhol ou inglês até julho de 2010, que comparassem o uso de antifúngicos azólicos e alilamínicos entre si ou com placebo, no tratamento de candidíase cutânea, e das tineas versicolor, pedis, cruris e corporis. Os desfechos de eficácia avaliados foram cura micológica ao final do tratamento e cura sustentada. RESULTADOS: Dos 4.424 estudos inicialmente identificados, 49 alcançaram os critérios de seleção, sendo incluídos nas metanálises. Os dados agrupados de eficácia demonstraram superioridade dos antifúngicos frente a placebo, independente da dermatomicose avaliada, com valores de odds ratio (OR) variando de 2,05 (IC 95% 1,18-3,54) a 67,53 (IC 95% 11,43-398,86). Alilaminas foram superiores aos azólicos apenas para o desfecho cura sustentada (OR 0,52 [IC 95% 0,31-0,89]). CONCLUSÃO: Há evidência consistente da superioridade dos antifúngicos com relação ao uso de placebo, não sendo mais justificável a realização de estudos controlados por placebo. Alilaminas mantêm a cura micológica por períodos mais extensos que fármacos azólicos. Dada a significativa diferença de custo entre as classes, recomenda-se a realização de análises farmacoeconômicas.


OBJECTIVE: To evaluate and compare the efficacy of topical antifungal drugs applied to the treatment of each dermatomycosis. METHODS: A systematic review of randomized clinical trials, published in Portuguese, Spanish and English until July 2010, which compared the use of azole and allylamine antifungal drugs among themselves and with placebo in the treatment of cutaneous candidiasis and T. versicolor, T. pedis, T. cruris and T. corporis was performed. The efficacy outcomes evaluated were mycological cure at the end of treatment and sustained cure. RESULTS: Of the 4,424 studies initially identified, 49 met the selection criteria and were included in the meta-analyses. The grouped efficacy data evidenced the superiority of antifungal drugs compared to placebo, regardless of the dermatomycosis under evaluation, with odds ratio values ranging from 2.05 (95% CI 1.18-3.54) to 67.53 (95% CI 11.43-398.86). Allylamines were better than azoles only for the outcome sustained cure (OR 0.52 [95% CI 0.31-0.89]). CONCLUSION: There is consistent evidence of the superiority of antifungal drugs over the use of placebo, and placebo-controlled studies are no longer justifiable. Allylamines maintain the mycological cure for longer periods compared to azole drugs. Given the significant cost difference among the classes, pharmacoeconomic analyses should be performed.


Assuntos
Humanos , Antifúngicos/administração & dosagem , Candidíase Cutânea/tratamento farmacológico , Tinha/tratamento farmacológico , Administração Cutânea , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento
19.
An. bras. dermatol ; 87(2): 250-255, Mar.-Apr. 2012. ilus, graf, tab
Artigo em Inglês | LILACS | ID: lil-622423

RESUMO

BACKGROUND: Trichophyton rubrum is the most common agent of superficial mycosis of the skin and nails causing long lasting infections and high recurrence rates. Current treatment drawbacks involve topical medications not being able to reach the nail bed at therapeutic concentrations, systemic antifungal drugs failing to eradicate the fungus before the nails are renewed, severe side effects and selection of resistant fungal isolates. Photodynamic therapy (PDT) has been a promising alternative to conventional treatments. OBJECTIVES: This study evaluated the in vitro effectiveness of toluidine blue O (TBO) irradiated by Light emitting diode (LED) in the reduction of T. rubrum viability. METHODS: The fungal inoculums' was prepared and exposed to different TBO concentrations and energy densities of Light emitting diode for evaluate the T. rubrum sensibility to PDT and production effect fungicidal after photodynamic treatment. In addition, the profiles of the area and volume of the irradiated fungal suspensions were also investigated. RESULTS: A small reduction, in vitro, of fungal cells was observed after exposition to 100 µM toluidine blue O irradiated by 18 J/cm² Light emitting diode. Fungicidal effect occurred after 25 µM toluidine blue O irradiation by Light emitting diode with energy density of 72 J/cm². The analysis showed that the area and volume irradiated by the Light emitting diode were 52.2 mm² and 413.70 mm³, respectively. CONCLUSION: The results allowed to conclude that Photodynamic therapy using Light emitting diode under these experimental conditions is a possible alternative approach to inhibit in vitro T. rubrum and may be a promising new treatment for dermatophytosis caused by this fungus.


FUNDAMENTOS: Trichophyton rubrum é o agente mais comum das micoses superficiais de pele e unhas causando infecções de longa duração e altas taxas de recidiva. As desvantagens do tratamento atual envolvem medicações tópicas as quais não são capazes de alcançar o leito ungueal em concentrações terapêuticas, antifúngicos sistêmicos que não erradicam o fungo antes das unhas serem renovadas, efeitos colaterais graves e seleção de isolados fúngicos resistentes. A terapia fotodinâmica tem sido uma alternativa promissora aos tratamentos convencionais. OBJETIVOS: Este estudo avaliou a eficácia, in vitro, de azul de orto-toluidina irradiado por diodo emissor de luz na redução da viabilidade de T. rubrum. MÉTODOS: O inóculo fúngico foi preparado e exposto a diferentes concentrações de azul de orto-toluidina e densidades de energia do diodo emissor de luz, para avaliar a sensibilidade de T. rubrum e o efeito fungicida, após terapia fotodinâmica. Além disso, os perfis da área e volume das suspensões fúngicas irradiados também foram investigados. RESULTADOS: Uma pequena redução, in vitro, de células fúngicas foi observada após a exposição a 100 mM azul de orto-toluidina irradiados por diodo emissor de luz a 18 J/cm². Efeito fungicida ocorreu após irradiação 25 µM orto-toluidina por diodo emissor de luz com densidade de energia de 72 J/cm². A análise mostrou que a área e o volume irradiados pelo diodo emissor de luz foram 52,2 mm² e 413,70 mm³, respectivamente. CONCLUSÕES: Os resultados permitiram concluir que a terapia fotodinâmica com diodo emissor de luz, nas condições experimentais é uma abordagem alternativa para inibir, in vitro, T. rubrum e pode ser um tratamento promissor para as dermatofitoses causadas por este fungo.


Assuntos
Fotoquimioterapia/métodos , Fármacos Fotossensibilizantes/uso terapêutico , Cloreto de Tolônio/uso terapêutico , Trichophyton/efeitos da radiação , Relação Dose-Resposta à Radiação
20.
An. bras. dermatol ; 86(4,supl.1): 182-185, jul,-ago. 2011. ilus, tab
Artigo em Português | LILACS | ID: lil-604154

RESUMO

A esporotricose é uma infecção subaguda ou crônica, causada por fungos pertencentes ao Complexo Sporothrix. Relato do caso: esporotricose de localização nasal foi tratada com iodeto de potássio e como não se obteve sucesso, reiniciou-se o tratamento com associação de iodeto de potássio e itraconazol. Porém, ocorreu nova recidiva. As culturas dos exames micológicos foram submetidas a ensaios de atividade antifúngica in vitro para auxiliar no tratamento. A terbinafina foi o antifúngico que apresentou melhores resultados, por isso, o tratamento foi reiniciado com este antifúngico e, após dois anos do término do mesmo, não recidivou. Adicionalmente, ambas as culturas foram comparadas por RAPD, obtendo padrões de fragmentos distintos, indicando que os isolados são diferentes ou demonstrando um processo microevolutivo do microrganismo.


Sporotrichosis is a chronic subacute infection caused by fungi belonging to the Sporothrix Complex. In the present clinical case, nasal sporotrichosis was treated with potassium iodide. This was unsuccessful, and the treatment was restarted with a combination of potassium iodide and itraconazole. This however resulted in a further recurrence of the infection. The mycological cultures were tested in vitro for antifungal activity to assist in treatment. Terbinafine, an antifungal drug, produced the best results and was therefore used for the rest of the treatment course, with no recurrence after two years of its completion. In addition, both cultures were compared using RAPD and different fragment patterns were observed. This indicated that the isolates were either different or indicated a microevolutionary process of this microorganism.


Assuntos
Idoso , Feminino , Humanos , Antifúngicos/uso terapêutico , Naftalenos/uso terapêutico , Doenças Nasais/tratamento farmacológico , Esporotricose/tratamento farmacológico , Testes de Sensibilidade Microbiana , Doenças Nasais/microbiologia , Sporothrix/isolamento & purificação , Esporotricose/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...